Macarena Rey

Medical oncologist at Gustave Roussy Institute

[Enrique Grande @drenriquegrande]

What great news!!!!! 👏👏👏👏👏👏👏
Perioperative Durvalumab plus EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial.
@OncoAlert @seom @CANVES_ES @GUOncologyNow @OncBrothers @myESMO

https://t.co/uOS52u6l7V

[Enrique Grande @drenriquegrande]

⚡️ @NEJM - Perioperative enfortumab vedotin + pembrolizumab improves outcomes in muscle-invasive bladder cancer.

In KEYNOTE-905:

• 2-year EFS: 74.7% vs 39.4% (HR 0.40)
• OS: HR 0.50
• pCR: 57.1% vs 8.6%

A potential new standard in cisplatin-ineligible patients.

#BladderCancer #Immunotherapy

https://t.co/1aWLXtmDq5

[Tom Powles @tompowles1]

This is the 2nd negative triplet study in 1st line metastatic kidney cancer - COSMIC 313 (ipi/nivo +\- cabo) was the other. It means sequencing doublets rather than giving everything upfront will be the standard of care for some time to come. Personalised therapy remained elusive in kidney cancer. @OncoAlert @DrChoueiri @brian_rini

[Tom Powles @tompowles1]

2️⃣ positive trials for belzutifan on the same day! LITESPARK-022 tests adjuvant belzutifan+pembro vs pembro alone post surgery in ccRCC. It is +ve for DFS. It’s the 1st +ve combination trial in adjuvant RCC & moves pateint care forward.@DrChoueiri https://t.co/8s5MvBU2NQ

[Toni Choueiri, MD @DrChoueiri]

Powerful talk by @DrRanaMcKay with an overview on #HIF2 inhibitors treatment landscape, #LITESPARK clinical trials comprehensive results and updates. Exciting data and future opportunities for #RCC therapy armentarium.
#ASCO25 @ASCO @ASCOPost @JCO_ASCO @neerajaiims @montypal @bergsa83 @GlopesMd @VivekSubbiah @OncoAlert @tompowles1 @OncBrothers @yekeduz_emre @ZiadBakouny @AminNassarMD @NazliDizman

[Tom Powles @tompowles1]

In STELLAR 002 #ASCO25 zanzalintinib nivolumab +/- rela (LAG3) demonstrated promising preliminary dinical actively for the doublet without clear benefit associated with adding LAG3. Triplets and targets beyond PD1 abs LAG3 both appear challanging as with COSMIC313

[Laurence Albiges @AlbigesL]

@KidneyCancer @minaseconomides @nachoduranm @TurajlicLab @LauraMarandino @macsrey @grantissimus Thanks for the invitation to this great Mentor -Mentee panel discussions #IKCSEU25 with @TurajlicLab @grantissimus
Huge thanks to @KidneyCancer for giving these opportunities to broadcast all the work of @GustaveRoussy young talents

[Kidney Cancer @KidneyCancer]

Superstar panel of mentors AND mentees at the young investigators panel this morning! #IKCSEU25

[Riccardo Campi @Ric_Campi]

📣Updated @Uroweb EAU Guidelines on #RenalCellCarcinoma 2025!

Read on @EUplatinum 👇
https://t.co/d7MAl6ET7D

Full version on @Uroweb 👇
https://t.co/mGQkCxIK19

#AxelBex #JensBedke @Yasminabugh @AlbigesL
@u_capitanio @DrDabestani @milanhoraplzen @Dr_Klatte #TeeleKuusk #LarsLund @Lorenzo_marconi
@CPalumbo87 @PignotG @tompowles1 #MaxineTran @foxal72

[José Mª Rey Benayas @josemreybenayas]

Ya está abierta la preinscripción del Máster U. en Restauración de Ecosistemas (https://t.co/RVFy8ccXqS). Toda la información de este Máster en https://t.co/vYDpgtHQiR

[Dr Amol Akhade @SuyogCancer]

What after IO plus Tki in advanced clear cell RCC ? Nice slide by @BourlonMaite @ASCO #GU25

[Michael Hofman @DrMHofman]

Longer follow-up from our landmark ProPSMA study just out @EurUrolOncol:

PSMA nodal status is prognostic! At 3 years 70% of patients without nodal involvement (N0) disease free, vs. only 46% if N1

CT-defined nodal status is not prognostic.

Read the details here: https://t.co/OWCrc3ui8P

Super team: @declangmurphy @veerukasi @ButeauJames @lawrentschuk @mj_robbo @DocJarad @mfrydenberg @DrAIravani

ProPSMA sponsored by @PeterMacCC
Funded by @PCFA @MovemberAUS
@pros_tic supported by @PCF_Science

[Pierre Blanchard, MD @PBlanchardMD]

Excellent discussion of pitfalls and practical implications of the PEACE 3 data by Prof Karim Fizazi.

1. Clinical benefit clear PFS/OS
2. Fracture prevention
3. BP monitoring
4. Only for ARPI naive pts
5. More data to come!

#ESMO2024

[Macarena Rey @macsrey]

RCC ESMO 2024 (TiNivo-2)
Once again, evidence against IO rechallenge but:
1) was Nivo unable to overcome the disadvantage of an underdosed Tivo? In the combo arm, Tivo at 0.89mg
2) @BraunMDPhD ‘s point on PD-1 receptor occupancy remains an issue when investigating IO after IO

[OncoAlert @OncoAlert]

Dear Colleagues,
The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟+1⃣ Abstracts on #BladderCancer and #KidneyCancer to be Presented at #ESMO24

This List Curated by: #OncoAlertAF Leads
@nataliagandur 🇦🇷
@yekeduz_emre 🇺🇸
@weoncologists 🇺🇸

and our distinguished faculty
@DrChoueiri 🇺🇸
@apolo_andrea 🇺🇸
@PGrivasMDPhD 🇺🇸
@drenriquegrande 🇪🇸
@TiansterZhang 🇺🇸
@montypal 🇺🇸
@DrDanielHeng 🇨🇦
@DrYukselUrun 🇹🇷
@gbanna74 🇬🇧
@ravikanesvaran 🇸🇬

LBA73 - Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune  Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study 
Presenter :Toni Choueiri🇺🇸 of @DanaFarber_GU
Discussant: @schmidingerRCC
Fri, 13.09.2024
14:00 - 14:10

LBA5 - A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) 
Presenter @tompowles1 🇬🇧
Discussant: Petros Grivas
Sun, 15.09.2024
17:14 - 17:26

LBA74 - Final analysis of the phase 3 LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Presenter:: @brian_rini 🇺🇸
Discussant: @schmidingerRCC
Fri, 13.09.2024
14:10 - 14:20

LBA84 - TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): interim analysis of SunRISe-4 (SR-4)
Presenter: @AndreaNecchi 🇮🇹
Discussant: @BogdanaSchmidt
Mon, 16.09.2024
08:50 - 09:00

1966MO - EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Presenter: @tompowles1 🇬🇧
Discussant Aristotelis Bamias
Sun, 15.09.2024
09:35 - 09:40

LBA85 - TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non–muscle-invasive bladder cancer (HR NMIBC): updated results from SunRISe-1 (SR-1)
Presenter: @MichvdHeijden 🇳🇱
Discussant: @mdesantis234
Sun, 15.09.2024
08:30 - 08:35

LBA77 - Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. Preliminary results of the randomized phase 2 TACITO trial.
Presenter: @ciccarese_c 🇮🇹
Discussant: Camillo Guglielmo Porta
Sun, 15.09.2024
09:05 - 09:10

1970MO - Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial 
Presenter: Alexandra Drakaki🇺🇸
Discussant: @mdesantis234
Sun, 15.09.2024
08:40 - 08:45

1961O - Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group
Presenter: Andromachi Kougioumtzopoulou 🇬🇷
Discussant: @shilpaonc
Mon, 16.09.2024
09:20 - 09:30

1964MO - Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs)
Presenter: @apolo_andrea 🇺🇸
Discussant: @mdesantis234
Sun, 15.09.2024
08:35 - 08:40

Ping OncoAlert GU faculty
@amerseburger @scserendipity1 @Silke_Gillessen @neerajaiims @cdanicas @EfstathiouEleni

#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo
@ElisaAgostinett @to_be_elizabeth @lungoncdoc @realbowtiedoc @Erman_Akkus @Lucarecco @gu_onc @Uromigos

[Macarena Rey @macsrey]

@Rodrosb @JAMAOnc @G_Villacampa @TomasPascualMD Congrats !

[Toni Choueiri, MD @DrChoueiri]

Updated @NCCN guidelines (1.2025) are in, with some major changes for systemic therapies:
1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC
3) Adjuvant Pembro is now Category 1

@kidneycan @KidneyCancer @DanaFarber_GU @BradMcG04 @bergsa83 @VincentWenxinXu @OncoAlert

[OncoAlert @OncoAlert]

Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials out on @JCO_ASCO

Study investigates the impact of immunosuppressive treatment💊 on survival in patients with various tumor types receiving anti–PD-1 + anti–CTLA-4 therapy🧪, utilizing data from six international phase II/III trials. The analysis included 834 out of 1,959 patients who were treated with corticosteroids for treatment-related adverse events (trAEs), with 10% also receiving second-line immunosuppressants.

✅Results showed that higher peak corticosteroid doses were significantly associated with worse PFS and OS, whereas cumulative corticosteroid dose was not linked to survival outcomes. Due to the limited number of patients receiving second-line immunosuppression, no definitive conclusions could be drawn regarding its impact on survival.

These findings suggest a need to reconsider current irAE management strategies, advocating for the use of lower corticosteroid doses when possible.

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth @anmwongNZ @lungoncdoc @ADesaiMD @bavilima @realbowtiedoc

[Tom Powles @tompowles1]

More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tivo alone in PD(L)1 pretreated RCC pts. ⬇️ Tivo dose in study arm requires consideration. This has implications post adjuvant pembro https://t.co/jelEQTIrn4

[Macarena Rey @macsrey]

@AinhoaMada @StephanieLheur5 @AnaOaknin @dvalcarcel @PerezFidal @CristinaSaura3 @Esanzgarcia Congratulations!